Impact of \u3cem\u3eMYH6\u3c/em\u3e Variants in Hypoplastic Left Heart Syndrome [PDF]
, 2016 Hypoplastic left heart syndrome (HLHS) is a clinically and anatomically severe form of congenital heart disease (CHD). Although prior studies suggest that HLHS has a complex genetic inheritance, its etiology remains largely unknown.
Benson, D. Woodrow +13 more
core +2 more sources
Tumor Growth Increases Neuroinflammation, Fatigue and Depressive-like Behavior Prior to Alterations in Muscle Function [PDF]
, 2015 Cancer patients frequently suffer from fatigue, a complex syndrome associated with loss of muscle mass, weakness, and depressed mood. Cancer-related fatigue (CRF) can be present at the time of diagnosis, during treatment, and persists for years after ...
Bicer, Sabahattin +8 more
core +2 more sources
TWO CLASSES OF MYOSIN INHIBITORS, BLEBBISTATIN AND MAVACAMTEN, STABILIZE β-CARDIAC MYOSIN IN DIFFERENT STRUCTURAL AND FUNCTIONAL STATES [PDF]
, 2020 ABSTRACTIn addition to a conventional relaxed state, a fraction of myosins in the cardiac muscle exists in a newly-discovered low-energy consuming super-relaxed (SRX) state, which is kept as a reserve pool that may be engaged under sustained increased cardiac demand.
Sampath K. Gollapudi +7 more
openaire +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
Journal of the American Heart Association, EarlyView., 2021 Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes +14 more
wiley +1 more source
Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. [PDF]
, 2019 The term "inotrope" is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock.
Adams, KF +7 more
core +2 more sources
The Journal of Clinical InvestigationThe myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj +1 more source
PLoS ONE, 2014 RationaleRescuing adverse myocardial remodeling is an unmet clinical goal and, correspondingly, pharmacological means for its intended reversal are urgently needed.ObjectivesTo harness a newly-developed experimental model recapitulating progressive heart
Oren Gordon +6 more
doaj +1 more source
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. [PDF]
PLoS ONE, 2010 Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia.
Kevin J Morine +5 more
doaj +1 more source
A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274 [PDF]
Journal of Cardiac Failure, 2019 Introduction Hypercontractility of the cardiac sarcomere appears to underlie pathological hypertrophy and fibrosis in select genetic hypertrophic cardiomyopathies (HCM). CK-3773274 (CK-274) decreases systolic function in preclinical models by directly binding to the cardiac myosin motor domain and inhibiting the myosin ATPase, stabilizing the motor in
Laura A. Robertson +6 more
openaire +1 more source